bullish
Adicet Bio Inc (ACET) - Thursday, Jul 18, 2024
SUMMARY
- Adicet Bio is a biotech company working on developing an off-the-shelf CD20 gamma delta CAR-T cell therapy for autoimmune diseases, particularly lupus nephritis
- The company also has gamma delta CAR-T programs targeting various cancers, with value inflection data points expected in 2024 and 2025
- Despite trading at a negative enterprise value, Adicet has significant cash reserves and a manageable quarterly spend, making its equity potentially underpriced compared to peers, with the potential success of its autoimmune program leading to a stock re-rating.
This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x